Tinlarebant is under clinical development by Belite Bio and currently in Phase III for Geographic Atrophy. According to GlobalData, Phase III drugs for Geographic Atrophy have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tinlarebant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tinlarebant overview

LBS-008 is under development for the treatment of geographic atrophy (GA) associated with dry AMD. and stargardt macular dystrophy (juvenile onset of macular degeneration). The drug candidate is administered through the oral route. The drug candidate acts by targeting retinol binding protein 4 (RBP4).

Belite Bio overview

Belite Bio is a clinical-stage biopharmaceutical drug development business focused on innovative treatments for untreatable retinal degeneration illnesses such as atrophic age-related macular degeneration and STGD1. The company is headquartered in United States.

For a complete picture of Tinlarebant’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.